// App-Quantinova.ai

: Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST

Researchers

Presenter

  • William Busse

Principal Investigators

  • Jorge F. Maspero

  • Contance H. Katelaris

  • Dinesh Saralaya

  • Sophie Guillonneau

  • Bingzhi Zhang

  • Christine Taniou

  • Heribert Staudinger

  • Jingdong Chao

  • Nikhil Amin

  • Gianluca Pirozzi

  • Marcella Ruddy

  • Bolanle Akinlade

  • Neil M. H. Graham

  • Ariel Teper

  • Asif Khan

Medical Centers

  • University of Wisconsin - Madison - United States of America

  • Fundacion GADOR, Buenos Aires, Argentina

  • Sydney University, Sydney, Australia

  • Bradford Institute for Health Research, Bradford, United Kingdom

  • Sanofi, Chilly-Mazarin, France

  • Experis IT, BU Pharma and Industry, Nanterre, France

  • Sanofi US, Bridgewater, United States of America

  • Regeneron Pharmaceuticals - Tarrytown - United States of America

Locations

  • United States

  • Argentina

  • Australia

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02414854

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved